|
Clinical activity, safety and tolerability of ASN002, a dual SYK/JAK inhibitor, in patients non-Hodgkin lymphoma (NHL) and solid tumors. |
|
|
|
Consulting or Advisory Role - TaiRx, Inc. |
Research Funding - Aeglea Biotherapeutics (Inst); Asana Biosciences (Inst); Bayer (Inst); Celgene (Inst); Eisai (Inst); Five Prime Therapeutics (Inst); Millennium (Inst); Pharmacyclics (Inst); Rexahn Pharmaceuticals (Inst); Santa Maria Biotherapeutics (Inst) |
|
|
No Relationships to Disclose |
|
|
Research Funding - Asana Biosciences (Inst); Genentech (Inst); Seagen (Inst) |
|
|
Research Funding - Asana Biosciences (Inst) |
|
|
|
Leadership - Symphony Evolution |
Consulting or Advisory Role - Akebia Therapeutics (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Bayer Schering Pharma (Inst); Bicycle Therapeutics (Inst); Blend Therapeutics (Inst); Boehringer Ingelheim (Inst); Celator (Inst); Elekta (Inst); Endocyte (Inst); Genmab (Inst); Heron (Inst); Ignyta (Inst); Janssen (Inst); Johnson & Johnson (Inst); MEDIAN Technologies (Inst); Merus (Inst); Nanobiotix (Inst); New B Innovation (Inst); OncoMed (Inst); Pierre Fabre (Inst); Rigontec (Inst); Symphony Evolution (Inst); Upsher-Smith (Inst); Zymeworks (Inst) |
Research Funding - AbbVie (Inst); ArQule (Inst); Asana Biosciences (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Cerulean Pharma (Inst); Dicerna (Inst); Endocyte (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Macrogenics (Inst); Otsuka (Inst); Pfizer (Inst); Plexxikon (Inst); TaiRx, Inc. (Inst) |
|
Niranjan Sathyanarayana Rao |
Employment - Asana Biosciences |
Leadership - Asana Biosciences |
Stock and Other Ownership Interests - Asana Biosciences |
|
|
Employment - Asana Biosciences |
Leadership - Asana Biosciences |
|
|
Employment - Asana Biosciences |
Leadership - Asana Biosciences |
Stock and Other Ownership Interests - Asana Biosciences |
|
|
Consulting or Advisory Role - Janssen Oncology |
Speakers' Bureau - Celgene; Janssen |
Research Funding - Celgene; Merck; Seagen |